Catherine E Willoughby

7PUBLICATIONS
46CO-AUTHORS
Major global burdens of diseaseMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 18, 2023
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment.

Josep M Llovet, Catherine E Willoughby, Amit G Singal

|Feb 13, 2023
Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma.

Jordi Abril-Fornaguera, Laura Torrens, Carmen Andreu-Oller

|Apr 28, 2022
CXCR2 inhibition enables NASH-HCC immunotherapy.

Jack Leslie, John B G Mackey, Thomas Jamieson

|Mar 18, 2022
Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma.

Roger Esteban-Fabró, Catherine E Willoughby, Marta Piqué-Gili

|Jun 22, 2021
Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.

Laura Torrens, Carla Montironi, Marc Puigvehí

|Jan 21, 2021
Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma.

Florian Castet, Catherine E Willoughby, Philipp K Haber

Pageof 2

Frequent Collaborators

6 joint publications

Josep M Llovet

4 joint publications

Laura Torrens

3 joint publications

Roser Pinyol

3 joint publications

Jordi Abril-Fornaguera